These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

295 related articles for article (PubMed ID: 30528077)

  • 1. Definitive or neoadjuvant chemoradiotherapy for squamous cell oesophageal cancer?
    Ilson D; Lordick F
    Lancet Oncol; 2018 Oct; 19(10):1285-1286. PubMed ID: 30528077
    [No Abstract]   [Full Text] [Related]  

  • 2. Multidisciplinary Therapy for Locally Advanced Oesophageal Cancer With Special Reference to Surgical Conversion and Salvage.
    Sohda M; Miyazaki T; Sakai M; Kumakura Y; Honjyo H; Hara K; Tanaka N; Yokobori T; Shirabe K
    Anticancer Res; 2019 Jun; 39(6):3167-3175. PubMed ID: 31177163
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Influence of Neoadjuvant Therapy on Poor Long-Term Outcomes of Postoperative Complications in Patients with Esophageal Squamous Cell Carcinoma: A Retrospective Cohort Study.
    Takeuchi M; Kawakubo H; Mayanagi S; Irino T; Fukuda K; Nakamura R; Wada N; Takeuchi H; Kitagawa Y
    Ann Surg Oncol; 2019 Jul; 26(7):2081-2089. PubMed ID: 30937664
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Is neoadjuvant chemotherapy combined with immunotherapy really better than neoadjuvant chemoradiotherapy in patients with esophageal squamous cell carcinoma?
    Li K; Yang J; Huang Y
    J Thorac Cardiovasc Surg; 2024 Aug; 168(2):e31-e32. PubMed ID: 38551555
    [No Abstract]   [Full Text] [Related]  

  • 5. Comparison of survival among neoadjuvant chemoradiation responders, non-responders and patients receiving primary resection for locally advanced oesophageal squamous cell carcinoma: does neoadjuvant chemoradiation benefit all?
    Hsu PK; Chien LI; Huang CS; Hsieh CC; Wu YC; Hsu WH; Chou TY
    Interact Cardiovasc Thorac Surg; 2013 Sep; 17(3):460-6. PubMed ID: 23728085
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Neoadjuvant chemotherapy combined with immunotherapy versus neoadjuvant chemoradiotherapy in patients with locally advanced esophageal squamous cell carcinoma.
    Yu YK; Meng FY; Wei XF; Chen XK; Li HM; Liu Q; Li CJ; Xie HN; Xu L; Zhang RX; Xing W; Li Y
    J Thorac Cardiovasc Surg; 2024 Aug; 168(2):417-428.e3. PubMed ID: 38246339
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Patterns and timing of recurrence in esophageal squamous cell carcinoma patients treated with neoadjuvant chemoradiotherapy plus esophagectomy.
    Nagaki Y; Motoyama S; Sato Y; Wakita A; Fujita H; Sasaki Y; Imai K; Minamiya Y
    BMC Cancer; 2021 Nov; 21(1):1192. PubMed ID: 34753448
    [TBL] [Abstract][Full Text] [Related]  

  • 8. PATHOLOGIC COMPLETE RESPONSE (YPT0 YPN0) AFTER CHEMOTHERAPY AND RADIOTHERAPY NEOADJUVANT FOLLOWED BY ESOPHAGECTOMY IN THE SQUAMOUS CELL CARCINOMA OF THE ESOPHAGUS.
    Andreollo NA; Beraldo GC; Alves IPF; Tercioti-Junior V; Ferrer JAP; Coelho-Neto JS; Lopes LR
    Arq Bras Cir Dig; 2018 Dec; 31(4):e1405. PubMed ID: 30539980
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Adjuvant chemoradiotherapy plus pembrolizumab for locally advanced esophageal squamous cell carcinoma with high risk of recurrence following neoadjuvant chemoradiotherapy: a single-arm phase II study.
    Guo JC; Huang TC; Kuo HY; Lin CC; Hsu FM; Cheng JC; Huang YL; Hsieh MS; Huang PM; Lee JM; Wu SL; Hsu CH
    Cancer Immunol Immunother; 2024 Sep; 73(11):230. PubMed ID: 39249605
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of long-term outcomes between esophagectomy and chemoradiotherapy after endoscopic resection of submucosal esophageal squamous cell carcinoma.
    Tanaka T; Ueno M; Iizuka T; Hoteya S; Haruta S; Udagawa H
    Dis Esophagus; 2019 Dec; 32(12):. PubMed ID: 30980070
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Salvage treatment for superficial local failure after definitive chemoradiotherapy for esophageal squamous cell carcinoma.
    Nagai Y; Yoshida N; Baba H
    Dig Endosc; 2020 Jan; 32(1):146. PubMed ID: 31535391
    [No Abstract]   [Full Text] [Related]  

  • 12. Accuracy of detecting residual disease after neoadjuvant chemoradiotherapy for esophageal squamous cell carcinoma (preSINO trial): a prospective multicenter diagnostic cohort study.
    Zhang X; Eyck BM; Yang Y; Liu J; Chao YK; Hou MM; Hung TM; Pang Q; Yu ZT; Jiang H; Law S; Wong I; Lam KO; van der Wilk BJ; van der Gaast A; Spaander MCW; Valkema R; Lagarde SM; Wijnhoven BPL; van Lanschot JJB; Li Z
    BMC Cancer; 2020 Mar; 20(1):194. PubMed ID: 32143580
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Residual Cancer Volume Predicts Clinical Outcome in Patients With Esophageal Squamous Cell Carcinoma After Neoadjuvant Chemotherapy.
    Nakao R; Konishi E; Fujiwara H; Otsuji E; Yokota I; Urata Y; Yanagisawa A
    Int J Surg Pathol; 2019 Oct; 27(7):713-721. PubMed ID: 31203677
    [No Abstract]   [Full Text] [Related]  

  • 14. Definitive chemoradiotherapy versus neoadjuvant chemoradiotherapy followed by surgery for stage II to III esophageal squamous cell carcinoma.
    Barbetta A; Hsu M; Tan KS; Stefanova D; Herman K; Adusumilli PS; Bains MS; Bott MJ; Isbell JM; Janjigian YY; Ku GY; Park BJ; Wu AJ; Jones DR; Molena D
    J Thorac Cardiovasc Surg; 2018 Jun; 155(6):2710-2721.e3. PubMed ID: 29548582
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison Between Esophagectomy and Definitive Chemoradiotherapy in Patients With Esophageal Cancer.
    Wang BY; Hung WH; Wu SC; Chen HC; Huang CL; Lin CH; Chen HS
    Ann Thorac Surg; 2019 Apr; 107(4):1060-1067. PubMed ID: 30571951
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Radiation dose and pathological response in oesophageal cancer patients treated with neoadjuvant chemoradiotherapy followed by surgery: a multi-institutional analysis.
    Thomas M; Borggreve AS; van Rossum PSN; Perneel C; Moons J; Van Daele E; van Hillegersberg R; Deng W; Pattyn P; Mook S; Boterberg T; Ruurda JP; Nafteux P; Lin SH; Haustermans K
    Acta Oncol; 2019 Oct; 58(10):1358-1365. PubMed ID: 31432736
    [No Abstract]   [Full Text] [Related]  

  • 17. Effects of Neoadjuvant Chemoradiotherapy on Pathological TNM Stage and Their Prognostic Significance for Surgically-treated Esophageal Squamous Cell Carcinoma.
    Hamai Y; Hihara J; Emi M; Furukawa T; Ibuki Y; Yamakita I; Kurokawa T; Okada M
    Anticancer Res; 2017 Oct; 37(10):5639-5646. PubMed ID: 28982881
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Practice pattern and risk of not receiving planned surgery after neoadjuvant chemoradiotherapy for locally advanced oesophageal squamous cell carcinoma.
    Hong TH; Kim TH; Lee G; Yun J; Jeon YJ; Lee J; Shin S; Park SY; Cho JH; Choi YS; Shim YM; Sun JM; Oh D; Kim HK
    Eur J Cardiothorac Surg; 2024 Jul; 66(1):. PubMed ID: 38913852
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Esophagectomy after chemoradiation: who and when to operate.
    Kim JY; Hofstetter WL
    Semin Thorac Cardiovasc Surg; 2012; 24(4):288-93. PubMed ID: 23465677
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Impact of the interval between neoadjuvant concurrent chemoradiotherapy and esophagectomy in the modern era: a population-based propensity-score-matched retrospective cohort study in Asia.
    Kuo YH; Chien YW; Chen PR; Feng CL; Li CC; Chien CR
    World J Surg Oncol; 2019 Dec; 17(1):222. PubMed ID: 31856840
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.